William Blair & Company
STML

William Blair & Company’s Stemline Therapeutics, Inc. STML Stock Holding History

William Blair & Company’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-9,022
Closed -$408K – 2051
2013
Q3 		$408K Buy
+9,022
New +$294K ﹤0.01% 1617

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

William Blair & Company's STML Position: Q4 2013 in Review

William Blair & Company sold out of Stemline Therapeutics, Inc. (STML) in Q4 2013, closing a stake of 9,022 shares — an estimated $408K sold.

William Blair & Company first reported a position in STML in Q3 2013 and held it in 1 quarter. The position peaked at $408K in Q3 2013. 69 funds tracked by Wall St. Rank hold STML as of Q4 2013.

  • William Blair & Company reported no remaining Stemline Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • William Blair & Company sold 9,022 Stemline Therapeutics, Inc. shares in Q4 2013, an estimated $408K.
  • William Blair & Company first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • William Blair & Company's Stemline Therapeutics, Inc. position peaked at $408K in Q3 2013.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2013.

Based on William Blair & Company's 13F filing for Q4 2013, filed 11 Feb 2014.